Premium
BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG
Author(s) -
Cramer P,
Fürstenau M,
Robrecht S,
Giza A,
Fink A. M,
Fischer K,
Langerbeins P,
Al Sawaf O,
Tausch E,
Schneider C,
Schetelig J,
Dreger P,
Böttcher S,
Kreuzer K. A,
Schilhabel A,
Brüggemann M,
Kneba M,
Wendtner C. M,
Stilgenbauer S,
Eichhorst B,
Hallek M
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.34_2879
Subject(s) - bendamustine , medicine , obinutuzumab , venetoclax , gastroenterology , ibrutinib , neutropenia , chronic lymphocytic leukemia , oncology , clinical endpoint , debulking , surgery , clinical trial , leukemia , cancer , chemotherapy , ovarian cancer